These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1085 related items for PubMed ID: 18307681

  • 1. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG.
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [Abstract] [Full Text] [Related]

  • 2. Definition of at-risk patients: dynamic variables.
    Emberton M.
    BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
    [Abstract] [Full Text] [Related]

  • 3. Definition of at-risk patients: baseline variables.
    Roehrborn CG.
    BJU Int; 2006 Apr; 97 Suppl 2():7-11; discussion 21-2. PubMed ID: 16507046
    [Abstract] [Full Text] [Related]

  • 4. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM.
    BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [Abstract] [Full Text] [Related]

  • 5. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M, Zinner N, Michel MC, Gittelman M, Chung MK, Madersbacher S.
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [Abstract] [Full Text] [Related]

  • 6. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J.
    BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
    [Abstract] [Full Text] [Related]

  • 7. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG.
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [Abstract] [Full Text] [Related]

  • 8. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Elhilali M, ALF-ONE Study Group.
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [Abstract] [Full Text] [Related]

  • 9. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB.
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M.
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [Abstract] [Full Text] [Related]

  • 13. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
    Emberton M, Elhilali M, Matzkin H, Harving N, van Moorselaar J, Hartung R, Alcaraz A, Vallancien G, Alf-One Study Group.
    Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Current role for combination therapy in male LUTS.
    Chung DE, Kaplan SA.
    Arch Esp Urol; 2010 Jun; 63(5):323-32. PubMed ID: 20587837
    [Abstract] [Full Text] [Related]

  • 16. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, CombAT Study Group.
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [Abstract] [Full Text] [Related]

  • 17. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA, McVary KT.
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [Abstract] [Full Text] [Related]

  • 18. Risk stratification for benign prostatic hyperplasia (BPH) treatment.
    Emberton M, Fitzpatrick JM, Rees J.
    BJU Int; 2011 Mar; 107(6):876-80. PubMed ID: 21265993
    [Abstract] [Full Text] [Related]

  • 19. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
    Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M.
    Eur Urol; 2004 May; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
    [Abstract] [Full Text] [Related]

  • 20. Long-term results of medical treatment in benign prostatic hyperplasia.
    Kim CI, Chang HS, Kim BK, Park CH.
    Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.